Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00414024 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
A Phase 3 study, sponsored by Novartis.
- Terminated
- Registry status
- Phase 3
- Development phase
- 11
- Enrollment target
NCT00414024 is a Phase 3 study that was terminated before completion, run by Novartis. The registered enrollment target is 11 participants.
The verdict
NCT00414024, a Phase 3 study, was terminated before completion, sponsored by Novartis.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of Tegaserod in opioid-induced constipation in patients with non-cancer pain. Patients who enter this study PRIOR to the core study (CHTF919N2201) interim analysis receive the treatment as follows: Patients will be randomly assigned to receive open label tegaserod 6 mg b.i.d. or tegaserod 12 mg o.d. using an allocation ratio of 1:1. Patients who enter this study AFTER the core study interim analysis receive the treatment as follows: Patients will be assigned to receive the selected tegaserod dose regimen (as determined by the core study interim analysis) in an open label fashion.
Interventions
- DRUG Tegaserod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2007-02 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00414024
The ClinicalTrials.gov registry entry for NCT00414024 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tegaserod is the first listed.
NCT00414024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00414024 about?
NCT00414024 is a clinical study titled "Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.". This study will evaluate the safety and efficacy of Tegaserod in opioid-induced constipation in patients with non-cancer pain. Patients who enter this study PRIOR to the core study (CHTF919N2201) interim analysis receive the treatment as follows: Patients will be randomly assigned to receive open ...
What is the current status of trial NCT00414024?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 11 participants. The study started on 2007-02. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00414024?
The interventions under investigation include: Tegaserod (DRUG).
Who is sponsoring clinical trial NCT00414024?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.